Alloy Therapeutics, Inc. is hosting a webinar titled Beyond Affinity: Multi-Parameter Optimization of Multispecific Building Blocks on October 28 at 11:00 a.m. ET featuring Dalton Markrush, Associate Director of Protein Analytics.

Alloy Therapeutics is a Product Development Organization dedicated to helping the global scientific community make better medicines together. We provide the integrated platforms, data, and capabilities partners need to advance medicines from discovery through development—without building a competing proprietary pipeline of our own. Trusted by more than 200 partners worldwide, including 18 of the top 50 biopharmaceutical companies, Alloy works side by side with innovators to enable the discovery and development of their next breakthrough medicines. With Alloy, partners can: • Discover antibodies and complex biologics through an expanding portfolio of in vivo and in vitro platforms integrated with AI, machine learning, and high-throughput experimentation. • Unlock intracellular targets through Keyway™, our fully integrated T cell receptor mimic (TCRm) discovery and development capabilities. • Advance next-generation RNA medicines using the AntiClastic™ cyclic RNA platform and our integrated genetic medicines capabilities. • Access preclinical and clinical development expertise designed to help promising programs reach their next milestone. • Build new biotechnology companies around differentiated science through 82VS, Alloy’s affiliated venture studio. Founded in 2017 and headquartered in Boston, Alloy operates globally across the United States, Europe, and Japan. We continually innovate to expand our platforms and capabilities, creating broader access to cutting-edge technology across the biotechnology community. Learn how we can make better medicines, together: https://www.alloytx.com/